Connor, Clark & Lunn Investment Management Ltd. Aurinia Pharmaceuticals Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 556,454 shares of AUPH stock, worth $4.48 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
556,454
Previous 454,259
22.5%
Holding current value
$4.48 Million
Previous $3.33 Million
50.08%
% of portfolio
0.03%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding AUPH
# of Institutions
227Shares Held
58.9MCall Options Held
949KPut Options Held
1.51M-
Black Rock Inc. New York, NY9.27MShares$74.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA8.43MShares$67.9 Million5.69% of portfolio
-
Armistice Capital, LLC New York, NY6.4MShares$51.5 Million0.81% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$32 Million2.55% of portfolio
-
State Street Corp Boston, MA2.92MShares$23.5 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.14B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...